CCM
GRCE

Connective Capital Management’s Grace Therapeutics GRCE Stock Holding History

Connective Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84,549
Closed -$391K – 93
2026
Q1 		$391K Buy
+84,549
New +$332K 0.32% 34

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Connective Capital Management's GRCE Position: Q2 2026 in Review

Connective Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2026, closing a stake of 84,549 shares — an estimated $391K sold.

Connective Capital Management first reported a position in GRCE in Q1 2026 and held it in 1 quarter. The position peaked at $391K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Connective Capital Management reported no remaining Grace Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Connective Capital Management sold 84,549 Grace Therapeutics shares in Q2 2026, an estimated $391K.
  • Connective Capital Management first reported a position in Grace Therapeutics in Q1 2026 and held it in 1 quarter.
  • Connective Capital Management's Grace Therapeutics position peaked at $391K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Connective Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.